Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The zones of discrimination for M-Score is as such:
An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.
Good Sign:
Beneish M-Score -2.5 no higher than -1.78, which implies that the company is unlikely to be a manipulator.
The historical rank and industry rank for Venus Medtech (Hangzhou)'s Beneish M-Score or its related term are showing as below:
HKSE:02500'
s Beneish M-Score Range Over the Past 10 Years
Min: -3.71 Med: -2.41 Max: -1.62
Current: -2.5
During the past 9 years, the highest Beneish M-Score of Venus Medtech (Hangzhou) was -1.62. The lowest was -3.71. And the median was -2.41.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:02500 vs ABT, SYK, MDT: Beneish M-Score Comparison
For the Medical Devices subindustry, Venus Medtech (Hangzhou)'s Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Venus Medtech (Hangzhou) Beneish M-Score vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Venus Medtech (Hangzhou)'s Beneish M-Score distribution charts can be found below:
* The bar in red indicates where Venus Medtech (Hangzhou)'s Beneish M-Score falls into.
The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.
The M-Score Variables:
The M-score of Venus Medtech (Hangzhou) for today is based on a combination of the following eight different indices:
M
=
-4.84
+
0.92 * DSRI
+
0.528 * GMI
+
0.404 * AQI
+
0.892 * SGI
+
0.115 * DEPI
=
-4.84
+
0.92 * 1.2467
+
0.528 * 1.1312
+
0.404 * 1.1643
+
0.892 * 0.6742
+
0.115 * 0.3842
-
0.172 * SGAI
+
4.679 * TATA
-
0.327 * LVGI
-
0.172 * 1.1468
+
4.679 * -0.034272
-
0.327 * 0.4997
=
-2.50
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.
DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.
DEPI
=
(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1))
/
(Depreciation_t / (Depreciaton_t + PPE_t))
=
(118.628 / (118.628 + 559.352))
/
(107.52 / (107.52 + 128.572))
=
0.174973
/
0.455416
=
0.3842
Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.
6. SGAI = Sales, General and Administrative expenses Index
Total accruals calculated as the change in working capital accounts other than cash less depreciation.
TATA
=
(IncomefromContinuingOperations_t
-
CashFlowsfromOperations_t)
/
TotalAssets_t
=
(NetIncome_t - NonOperatingIncome_t
-
CashFlowsfromOperations_t)
/
TotalAssets_t
=
(-450.389 - 0
-
-354.999)
/
2783.346
=
-0.034272
An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.
Venus Medtech (Hangzhou) has a M-score of -2.50 suggests that the company is unlikely to be a manipulator.
Venus Medtech (Hangzhou) (HKSE:02500) has a Beneish M-Score of -2.50 as of Aug. 03, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Venus Medtech (Hangzhou) and its competitors. According to the industry distribution chart, Venus Medtech (Hangzhou) ranks #443 out of 762 companies in the Medical Devices & Instruments industry, placing it in the top 58.1%.
Is Venus Medtech (Hangzhou)'s Beneish M-Score too high?
Venus Medtech (Hangzhou)'s current Beneish M-Score is -2.50. Based on the distribution chart, Venus Medtech (Hangzhou) ranks #443 out of 762 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Venus Medtech (Hangzhou) has a GF Score™ of 52/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Venus Medtech (Hangzhou)'s Beneish M-Score compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Venus Medtech (Hangzhou) ranks #443 out of 762 companies for Beneish M-Score. This places Venus Medtech (Hangzhou) in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Medical Devices & Instruments company?
A good Beneish M-Score depends on the Medical Devices & Instruments industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Venus Medtech (Hangzhou) and its competitors. Venus Medtech (Hangzhou)'s current Beneish M-Score is -2.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Venus Medtech (Hangzhou) stock overvalued right now?
Based on GuruFocus' analysis, Venus Medtech (Hangzhou) (HKSE:02500) is currently considered Possible Value Trap. The stock's GF Value™ is HK$3.35, compared to a current price of HK$1.10 — trading 67.2% below its estimated fair value. The current Beneish M-Score is -2.50. Venus Medtech (Hangzhou)'s overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Venus Medtech (Hangzhou) (HKSE:02500), the current Beneish M-Score is -2.50 as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Venus Medtech (Hangzhou) (HKSE:02500) Overvalued in 2026?
Based on GuruFocus' analysis, Venus Medtech (Hangzhou) stock appears to be undervalued.
The current stock price of HK$1.10 is trading 67.2% below its estimated GF Value™ of HK$3.35.
GuruFocus considers Venus Medtech (Hangzhou) to be Possible Value Trap.
Key valuation signals for HKSE:02500:
Beneish M-Score: -2.50
GF Value™: HK$3.35 vs. price of HK$1.10 (67.2% below fair value)
No single metric tells the full story. See the HKSE:02500 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Venus Medtech (Hangzhou) Inc is engaged in the medical devices that integrate R&D, clinical development, manufacturing, and commercialization. The company has developed a product portfolio covering the interventional devices for valvular heart diseases, including transcatheter aortic valve replacement (TAVR), transcatheter pulmonary valve replacement (TPVR), transcatheter mitral valve replacement (TMVR), transcatheter tricuspid valve replacement (TTVR), and other procedural accessories, allowing it to provide overall solutions for physicians and patients. Geographically, the company operates in mainland China, Israel, Hong Kong, the USA, and the Netherlands. The majority of the revenue is derived from Mainland China.
52GF Score
Get the complete analysis for HKSE:02500
Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02500 has been successfully added to your 
